ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Free Cash Flow
    • Future ETFs
    • Global Diversification
    • Gold/Silver/Critical Minerals
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Megatrends
    • Modern Alpha
    • Multi-Asset
    • Night Effect
    • Portfolio Strategies
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • Company
    • About Us
    • Swag Store
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Disruptive Technology Channel
  2. The Molecular Biology Future Is Here
Disruptive Technology Channel
Share

The Molecular Biology Future Is Here

Tom LydonFeb 15, 2022
2022-02-15

Molecular biology sounds like a daunting academic subject, but it also has some compelling investment implications. Those are accessible in the genomics space, and long-term investors might want to pay attention because if certain forecasts prove accurate, molecular biology’s growth trajectory is likely to be exponential.

Among the various genomics exchange traded funds, the ARK Genomic Revolution Multi-Sector Fund (ARKG A-) is a prime idea to consider for molecular biology exposure due in part to ARKG’s reputation for often being ahead of the healthcare advancements curve.

“According to ARK’s research, the multi-omics revenue opportunity—including life science tools, basic and translational research, population health efforts, and molecular diagnostics—will scale at a 22% annual rate, from roughly $110 billion to $300 billion, during the next five years,” says ARK Investment Management analyst Simon Barnett.

At the core of the molecular biology thesis is the leveraging of other capabilities, including genomics, transcriptome, and proteome. Further enhancing molecular biology as an investable concept is the fact that it intersects with other disruptive technologies, including artificial intelligence and software. For ARKG investors, that’s potentially encouraging because some of the fund’s holdings are already proving proficient at leveraging other innovative technologies.

“Created using next-generation sequencing (NGS), the 2003 human genome draft sequence was incomplete. Using a combination of long-read sequencing (LRS) methods, the Telomere-to-Telomere (T2T) Consortium finally published a complete human genome–discovering 200 million more base pairs (bps) of DNA and 1,500 new genes in the process,” adds Barnett. “ARK believes this monumental achievement is a harbinger of novel life science tools and methods that will surface previously hidden biology.”

Putting that into plain English, advancements in molecular biology could bring to life new healthcare concepts that have the potential to lead to better cost efficiencies in healthcare and improved patient outcomes. Technology is at the center of those objectives, including scientists’ efforts to apply genomics concepts to discover new proteins.

“Genomics sequencing massively parallelized the analysis of DNA and RNA data, enabling a significant increase in research experiments,” concludes Barnett. “Several new detection technologies could parallelize the detection and analysis of proteins. ARK estimates that scientists will be able to quantify more than half* the human plasma proteome in a single experiment by the end of 2022.”

For more news, information, and strategy, visit the Disruptive Technology Channel.

Loading Articles...
Help & Info
  • Contact Us
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X